- Abstract
- Keywords
- Introduction
- Chemistry of BD
- Antineoplastic effects of BD in human malignancies
- Anti-metastatic effects of BD
- Potential anti-inflammatory effects of BD
- Pharmacokinetics, toxicity and metabolism
- Clinical application of BD
- Conclusion and future directions
- Abbreviations
- Declarations
- References
-
Citing Article List
The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease”.No. Publication Date Citing Article 1 2024 Ishfaq Ahmad Ahanger, Tanveer Ali Dar. Small molecule modulators of alpha-synuclein aggregation and toxicity: Pioneering an emerging arsenal against Parkinson’s disease, Ageing Research Reviews. 2024; 101: 102538102538. https://doi.org/10.1016/j.arr.2024.102538 2 2024 Anns Mahboob, Hasan Ali, AlJazi AlNaimi, Mahmoud Yousef, Mlaak Rob, Nawaf Ahmad Al-Muhannadi, Degiri Kalana Lasanga Senevirathne, Ali Chaari. Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy, Cells. 2024; 13: 1527. https://doi.org/10.3390/cells13181527 3 2024 Emma Boström, Sagar S. Bachhav, Hao Xiong, Cindy Zadikoff, Qingbo Li, Eric Cohen, Ingeborg Dreher, Anna Torrång, Gunilla Osswald, Mikael Moge, Paulina Appelkvist, Johanna Fälting, Tomas Odergren. Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults, The Journal of Clinical Pharmacology. 2024; 64: 1432. https://doi.org/10.1002/jcph.6103 -
